Markets:

Overview

News

Currencies

International

Treasuries

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

6.380 -0.060 (-0.93%)

Streaming Delayed Price Updated: 4:00 PM EST, Dec 5, 2025 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Aquestive Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 5 Next >

Jim Cramer: Joby Is 'Losing Too Much Money' ↗

November 12, 2025

Jim Cramer finds Aquestive Therapeutics very interesting, while Amphenol Corporation is a great stock. Joby Aviation is losing money.

Via Benzinga

Earnings Scheduled For November 5, 2025 ↗

November 05, 2025

Via Benzinga

Friday's session: gap up and gap down stocks ↗

September 26, 2025

Let's have a look at the gap up and gap down stocks in today's session.

Via Chartmill

Crinetics Pharmaceuticals, BlackBerry, Perpetua Resources And Other Big Stocks Moving Higher On Friday ↗

September 26, 2025

U.S. stocks were higher, with the Dow Jones index gaining more than 200 points on Friday. Shares of Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) rose sharply during Friday's session after the FDA...

Via Benzinga

Topics Stocks

Aquestive Stock Jumps After-Hours As CEO Sees $1B ‘Blockbuster’ Potential For Oral Allergy Film — Retail Sees Stock As Buyout Candidate ↗

September 26, 2025

Via Stocktwits

FDA Says No Advisory Committee Meeting Needed For Aquestive’s Oral Epinephrine Film ↗

September 04, 2025

Via Stocktwits

Aquestive Therapeutics Stock Is Rising Pre-Market – Its $75M Funding Agreement Draws Divided Opinions From Retail ↗

August 14, 2025

Via Stocktwits

Earnings Scheduled For May 12, 2025 ↗

May 12, 2025

Via Benzinga

ARS Pharma Urges FDA To Delay Approval Of Aquestive's Allergic Reaction Treatment ↗

September 23, 2025

ARS Pharmaceuticals petitioned the FDA to delay approval of Aquestive's epinephrine film, citing safety, dosing, and cardiovascular concerns.

Via Benzinga

12 Health Care Stocks Moving In Friday's Intraday Session ↗

September 19, 2025

Via Benzinga

CoreWeave, Barrick Mining, FedEx And Other Big Stocks Moving Higher On Friday ↗

September 19, 2025

Via Benzinga

Which stocks are gapping on Friday? ↗

September 19, 2025

The market is filled with gapping stocks in Friday's session. Let's discover which stocks are showing gap-ups and gap-downs.

Via Chartmill

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

September 04, 2025

Via Benzinga

Shoe Carnival, American Eagle, Ciena, Victoria's Secret And Other Big Stocks Moving Higher On Thursday ↗

September 04, 2025

Via Benzinga

FDA Confirms Direct Review Path For Aquestive's Allergy Treatment ↗

September 04, 2025

Aquestive's Anaphylm could become the first oral epinephrine for severe allergic reactions after the FDA set a 2026 decision date without panel review.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Pre-Market Session ↗

September 04, 2025

Via Benzinga

10 Health Care Stocks Whale Activity In Today's Session ↗

August 14, 2025

Via Benzinga

Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗

August 08, 2025

Via Benzinga

Uncovering Potential: Aquestive Therapeutics's Earnings Preview ↗

May 09, 2025

Via Benzinga

Aquestive Therapeutics Concludes FDA Application For Allergy Drug With Encouraging Pediatric Trial Data ↗

April 01, 2025

Aquestive's Anaphylm sublingual film met key pediatric study goals, supporting its NDA submission to the FDA for potential approval in 2025.

Via Benzinga

Aquestive Therapeutics Stock Dips After-Hours On Q4 Miss — Retail Eyes Silver Linings ↗

March 05, 2025

Stocktwits users are viewing the company's cash position, expectations for a late 2026 Anaphylm launch, and an upcoming trial as positive signals.

Via Stocktwits

Earnings Scheduled For August 11, 2025 ↗

August 11, 2025

Via Benzinga

Curious about the stocks that are showing activity after the closing bell on Wednesday? ↗

March 05, 2025

As the regular session of the US market on Wednesday comes to an end, let's delve into the after-hours session and discover the top gainers and losers shaping the post-market sentiment.

Via Chartmill

Earnings Scheduled For March 5, 2025 ↗

March 05, 2025

Via Benzinga

Developer Of EpiPen Alternative Aquestive Stock Undervalued Despite Strong Clinical Data, Analyst Sees Huge Upside ↗

December 17, 2024

Cantor initiates coverage on Aquestive Therapeutics, highlighting Anaphylm's potential to disrupt the epinephrine auto-injector market with 200% upside.

Via Benzinga

Optimism Around Aquestive As it Moves Forward With Severe Allergy, Baldness Candidate ↗

September 30, 2024

Aquestive Therapeutics hosted a virtual investor day, announcing advancements in Anaphylm and AQST-108. The company aims for FDA meetings in late 2024, targeting a 2025 NDA submission, while HC...

Via Benzinga

Oral Allergy Medication For Emergencies - Aquestive Therapeutics' Investigational Therapy Works Even With Exposure To Liquids Of Different Temperatures, Data Shows ↗

June 25, 2024

Aquestive Therapeutics released topline pharmacokinetic data for Anaphylm (epinephrine) Sublingual Film for severe allergic reactions.

Via Benzinga

AQST Stock Earnings: Aquestive Therapeutics Misses EPS, Misses Revenue for Q1 2024 ↗

May 07, 2024

AQST stock results show that Aquestive Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024.

Via InvestorPlace

12 Health Care Stocks Moving In Monday's Intraday Session ↗

April 29, 2024

Via Benzinga

Ally Financial Reports Upbeat Earnings, Joins Badger Meter, Genuine Parts And Other Big Stocks Moving Higher On Thursday ↗

April 18, 2024

Via Benzinga

< Previous 1 2 3 4 5 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

Aquestive Therapeutics, Inc. - Common Stock (NQ:AQST)

Headline News about Aquestive Therapeutics, Inc. - Common Stock

Starting at $3.75/week.

Subscribe Today